Therapeutic biaryl derivatives

The present invention relates to therapeutic biaryl derivatives of formula (i), and pharmaceutically acceptable derivatives thereof; wherein R1 is a phenyl, naphthyl, pyridyl, thiazolyl, phenoxymethyl, or pyrimidyl group, optionally substituted by one or more substituents selected from the group consisting of halogen, hydroxy, c1-6alkoxy, c1-6alkyl, nitro, cyano, hydroxymethyl, trifluoromethyl, -nr6r6, and -nhso2r6, where each r6 is independently hydrogen or C1-4alkyl; R2 is hydrogen or C1-6alkyl; X is oxygen, sulfur, -NH, or -NC1-4alkyl; R3 cyano, tetrazol-5-YL, or -CO2r7 where R7 is hydrogen or C1-6alkyl; R4 and R5 are independently hydrogen, C1-6alkyl, -CO2h, -CO2C1-6alkyl, cyano, tetrazol-5-YL, halogen, trifluoromethyl, or C1-6alkoxy, or, when R4 and R5 are bonded to adjacent carbon atoms, R4 and r5 may, together with the carbon atoms to which they are bonded, form a fused 5 or 6 membered ring optionally containing one or two nitrogen, oxygen, or sulfur atoms; and y is n or ch, to processes for their preparation and their use in the treatment of diseases susceptible to amelioration by treatment with a beta-3 adrenoceptor agonist.